|
Guidance Could Propel Breast Cancer Drugs to Market a Decade Sooner
Drugmakers could bring breast cancer treatments to market a decade earlier with new FDA guidance on trial designs for evaluating pathologic complete response (pCR) to support accelerated approval of drugs to treat high-risk, early-stage breast cancer.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives